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IMMUNOBIOLOGY
Lack of antigen-specific tissue remodeling in mice deficient in the macrophage
galactose-type calcium-type lectin 1/CD301a
Kayoko Sato, Yasuyuki Imai, Nobuaki Higashi, Yosuke Kumamoto, Thandi M. Onami, Stephen M. Hedrick, and Tatsuro Irimura
Macrophage galactose-type C-type lec-
tins (MGLs), which were recently named
CD301, have 2 homologues in mice: MGL1
and MGL2. MGLs are expressed on mac-
rophages and immature dendritic cells.
The persistent presence of granulation
tissue induced by a protein antigen was
observed in wild-type mice but not in
mice lacking an endogenous, macro-
phage-specific, galactose-type calcium-
type lectin 1 (MGL1) in an air pouch
model. The anti-MGL1 antibody sup-
pressed the granulation tissue formation
in wild-type mice. A large number of cells,
present only in the pouch of MGL1-
deficient mice, were not myeloid or lym-
phoid lineage cells and the number signifi-
cantly declined after administration of
interleukin 1  (IL-1) into the pouch of
MGL1-deficient mice. Furthermore, granu-
lation tissue was restored by this treat-
ment and the cells obtained from the
pouch of MGL1-deficient mice were incor-
porated into the granulation tissue when
injected with IL-1. Taken together, MGL1
expressed on a specific subpopulation of
macrophages that secrete IL-1 was pro-
posed to regulate specific cellular interac-
tions crucial to granulation tissue forma-
tion. (Blood. 2005;106:207-215)
© 2005 by The American Society of Hematology
Introduction
Granulation tissue formation is a consequence of chronic cellular
immune responses associated with persistent infection or autoimmunity.
Granulation tissue and chronic tissue fibrosis are formed and maintained
by macrophages and other myelomonocytic cells1-4 that produce cyto-
kines such as interleukin 1  (IL-1). These cytokines are thought to
increase fibroblast proliferation and collagen production which, in turn,
induce tissue remodeling.5-9 Although it is widely noted that fibrosis
constitutes an important final stage of the chronic cellular immune
response, and the contribution of T cells, macrophages, and fibroblasts
has been documented,10 the molecular mechanisms governing the
interactions of these cells are still obscure.
Macrophages and related cells are the predominant arm of
cellular immunity involved with sensitization, inflammation, and
tissue remodeling through cellular interactions and production of
soluble factors.11,12 The interactions of macrophages with extracel-
lular milieu are mediated by a variety of cell surface recognition
molecules including lectins, the carbohydrate-recognition proteins.
Lectins expressed on these cells include galectins, particularly
galectin-3; siglecs such as sialoadhesin; and many calcium-type
(C-type) lectins.13,14 These lectins are known to be involved in
endocytosis,15,16 cell adhesion,17 and cellular trafficking.18,19
The macrophage galactose-type calcium-type lectins (MGLs; CD301)
constitute a unique class of C-type lectins because of their specificity for
galactose and its structural homologues.20,21 In mice, we have recently
found that 2 closely related MGLs, termed MGL1 and MGL2 (CD301a
and CD301b), have different carbohydrate specificity, though their
distinct biologic roles are unknown.21 MGLs/CD301 are type II
transmembrane glycoproteins and are expressed on macrophages and
related cells of myeloid origins, particularly immature dendritic cells
(DCs).22 Using a monoclonal antibody (mAb) reactive to both MGL1
and MGL2, these lectins were shown to be expressed on connective
tissue macrophages, such as those in dermis, subdermic regions of skin,
lamina propria in the gastrointestinal tract, bronchiole-associated connec-
tive tissues, perivascular regions in a variety of organs and tissues, and
lymphoid organs.23-25 Bone marrow–derived DCs and thioglycollate-
induced peritoneal exudate cells were previously shown to express both
MGL1 and MGL2.21,22 However, the distribution of MGL1-positive
cells and MGL1-negative cells within several organs seems to be
distinct. For example, MGL1-positive/MGL2-positive cells and MGL1-
positive/MGL2-negative cells but not MGL1-negative/MGL2-positive
cells were present in dermis. MGL1, having a tyrosine internalization
motif, was previously shown to be involved in endocytosis of galactose-
terminated glycoconjugates in vitro. However, homozygous MGL1-
deficient mice seemed to be healthy and immunologically competent as
long as they were maintained under specific pathogen-free condi-
tions.21,26 The possibility that this is due to compensation by MGL2
remains to be elucidated.
MGL1/2-positive cells (reactive with mAb LOM-14) have been
shown to be involved in the sensitization phase of antigen-
dependent contact hypersensitivity.27-29 Upon epicutaneous sensiti-
zation with a hapten, we found that trafficking of MGL1/2-positive
macrophages from the topical site of the hapten application to the
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draining lymph nodes occurred. The extent of the macrophage
trafficking appeared to be positively correlated to the efficiency of
the sensitization.27 Furthermore, sialoadhesin (siglec-1) has re-
cently been identified as an endogenous ligand of MGL1 in lymph
nodes.30 Persistent antigen-specific stimulation within the dorsal air
pouch also results in granulation tissue formation and the accumu-
lation of MGL1/2-positive cells in the remodeled tissue.31 Staining
with antibodies specific for CD31, a marker for vascular endothe-
lial cells, strongly suggested the presence of chronic granulation
tissue. In this experimental model, MGL1/2-positive cells appar-
ently produced and secreted IL-1 and acted through this cytokine.
In the present report, we provide direct evidence that MGL1 is
causally involved in granulation tissue formation associated with
an antigen-specific cellular immune response. Using an air pouch
model, we show that MGL1-deficient mice or mice injected with
anti-MGL1 antibody exhibit substantially reduced granulation
tissue formation. Furthermore, the role of IL-1 was established by
blocking antibodies, or the partial reconstitution of granulation
tissue formation in MGL1-deficient mice resulting from the
injection of IL-1. The most likely interpretation of these results is
that tissue localization of important inflammatory cells is MGL1
dependent, and, as a consequence, the local delivery of IL-1 was
reduced. These observations should lead to an understanding of the
molecular mechanism of granulation tissue formation that mimics
the late stages of persistent infections and systemic sclerosis.
Materials and methods
Mice
MGL1-deficient mice of C57BL/6 background were used.26 Heterozygotes
were bred in the animal facility of the Graduate School of Pharmaceutical
Sciences of the University of Tokyo to obtain MGL1-deficient mice and
their wild-type control. Nine backcross generations were carried out to
C57BL/6. All animal experiments were performed in accordance with the
guidelines of the Bioscience Committee of the University of Tokyo and
were approved by the Animal Care and Use Committee of the Graduate
School of Pharmaceutical Sciences of the University of Tokyo.
Antigen and antibody
Azobenzene arsonate–conjugated acetylated bovine serum albumin (ABA-
AcBSA) was prepared as described.32 A rat mAb LOM-14 reactive to both
MGL1 and MGL2 and a rat mAb LOM-8.7 reactive only to MGL1 have
been described previously.24 Preparation and characterization of rat mAbs
specific for MGL2 and URA-1 will be described elsewhere (S. Aida, K.
Denda-Nagai, and T.I., manuscript in preparation).
Antigen-induced granulation tissue formation in mouse skin
Mice (wild-type or MGL1-deficient) were subcutaneously immunized with 200
g ABA-AcBSA emulsified 1:1 in complete Freund adjuvant (CFA; Difco,
Detroit, MI) as described previously.31 In brief, mice preimmunized with
ABA-AcBSA were repeatedly challenged in dorsal air pouches. Skin samples
covering the air pouch were collected on days 4, 11, and 18, and concurrently,
serum samples were taken by tail phlebotemy. In some experiments, cells in the
pouch fluid were collected on days 1 to 5 and were analyzed for the
expression of cell surface markers by flow cytometry, as described in
“Flow cytometric analysis.”
Humoral immune response
The total immunoglobulin G (IgG) concentration in serum was determined
with the mouse IgG enzyme-linked immunosorbent assay (ELISA) Quanti-
tation Kit (Bethyl Laboratories, Montgomery, TX) according to the
supplier’s instructions. To determine antigen-specific IgG levels in the
serum samples, an ELISA was performed as follows: ABA-AcBSA
solutions (100 g/mL, 100 L/well) were added and incubated overnight.
The wells were blocked with 1% BSA dissolved in 50 mM Tris/HCl buffer
(pH 8.0) containing 0.14 M NaCl (Tris-buffered saline [TBS]) before
adding serum samples serially diluted in TBS containing 1% BSA and
0.05% Tween 20 (TBS-BSA-Tween). After incubation, horseradish peroxi-
dase (HRP)–conjugated goat anti–mouse IgG-Fc (Bethyl) diluted in
TBS-BSA-Tween (1:50 000) was added and antigen-bound IgG was
detected by incubation with a substrate solution (3,3,5,5-tetramethyl
benzidene [TMB]; Kirkegaard & Perry, Gaithersburg, MD). After
addition of 50 L of 2 M H2SO4 to stop reactions, absorbance was
determined at 450 nm.
Antigen-specific proliferation of splenocytes
Mice (MGL1-deficient or wild-type mice) were immunized by intradermal
injection of ABA-AcBSA in CFA at 200 g/mouse. Three weeks later, the
splenocytes were collected by collagenase D digestion and were cultured in
96-well microculture plates, at a density of 2  105 cells/well, in 200 L
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), in
the presence or absence of various concentrations of ABA-AcBSA (3
g/mL-300 g/mL) for 5 days. To assess the lymphocyte proliferation,
cultures were pulsed with [3H]-thymidine (Amersham, Piscataway, NJ) for
the last 16 hours and radioactivity incorporated into insoluble fraction in
5% trichloroacetic acid was measured.
Treatment of anti-MGL1or anti–IL-1 antibodies in vivo
One hundred microliter solutions of anti–IL-1 mAb (Genzyme, Cam-
bridge, MA; 5 g/mouse), anti-MGL1 mAb LOM-8.7 (25 g/mouse), rat
IgG (Caltag, Burlingame, CA; 5 g/mouse), or saline were injected into the
air pouch on days 5, 6, and 7. Skin samples from the air pouch were
obtained on days 11 and 18, and were analyzed for the thickness of
granulation tissue. To examine the number of cells in the granulation tissue
in the absence or presence of anti-MGL1 antibody, subdermal granulation
tissue that formed after the challenge at the site of the air pouch was peeled
from the skin. The tissue samples were cut with scissors into 2-mm cubes,
and the fragments were incubated in 0.5% collagenase. Cells released from
the tissue were washed and resuspended in phosphate-buffered saline
(PBS), and then the number of cells was counted.
Treatment of recombinant mouse IL-1 in vivo
Solutions of recombinant mouse IL-1 (50 g/mL; 100 L/mouse) or PBS
were injected into the air pouch on day 0. Skin samples from the air pouch
were obtained on day 4 and were analyzed for the thickness of granulation
tissue. Cells in the pouch were collected on days 3 and 4, washed by
centrifugation in saline, and analyzed for their cell surface markers by flow
cytometry. In other experiments, 100-L solutions of IL-1 (5 g/mouse)
or PBS were injected into the air pouch on day 5. Skin samples from the air
pouch were obtained on day 11 and analyzed for the thickness of
granulation tissue.
In other experiments, the migrated cells from MGL1-deficient mice on
day 3 were collected and CD45-negative cells were isolated by magnetic
activated cell sorting (MACS) using mAb rat anti–mouse CD45 (30-F11,
rat IgG2a; BD Pharmingen, San Diego, CA) and goat anti–rat  light chain
microbeads (Miltenyi, Bergisch Gladbach, Germany) according to the
supplier’s instructions. The isolated cells were labeled with PKH26 (Sigma
Chemical, St Louis, MO) and were injected with 100-L solutions of IL-1
(5 g/mouse) or PBS into the air pouch on day 3. Skin samples were
obtained on day 6 and were analyzed by immunohistochemistry.
Flow cytometric analysis
Cells (1  106) were incubated for 60 minutes on ice with either: biotin rat
anti–mouse MGL1/2 mAb LOM-14 (1 g/mL); biotin-conjugated mAb rat
anti–mouse CD11b (M1/70.15, Caltag; 1 g/mL); fluorescein isothiocya-
nate (FITC)–conjugated mAb rat anti–mouse CD45 (Pharmingen; 1 g/mL);
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F4/80 (Caltag; 1 g/mL); or moma-2 (1 g/mL). As controls, purified rat
IgG2b (Zymed Laboratories, South San Francisco, CA; 1 g/mL), biotin-
conjugated rat IgG (eBiosciences, San Diego, CA; 1 g/mL), or FITC-
conjugated rat IgG (eBiosciences; 1 g/mL) were used. After being washed
twice with PBS containing 0.1% BSA, 0.1% NaN3 (F-PBS), cells were
incubated with FITC-conjugated mAb anti–rat  and  light chains (Sigma;
1:100 dilution) or FITC-conjugated streptavidin (Zymed; 1:100 dilution)
for 30 minutes on ice. The cells were then treated with propidium iodide
(PI; 5 g/mL in F-PBS) and were analyzed on a flow cytometer (EPICS
XL; Beckman Coulter, Fullerton, CA) by collecting data only from
PI-unstained cells.
Immunohistochemistry
Cells expressing MGLs were immunohistochemically detected using mAb
LOM-14 (1 g/mL), mAb LOM-8.7 (1 g/mL), or mAb URA-1 (1
g/mL). The binding of the mAbs was detected by a biotinylated mouse
mAb to rat  and  chains and alkaline phosphatase–streptavidin as
described previously.25,33 As a negative control, the sections were incubated
with rat IgG2b in place of the primary mAb. Some sections were stained
with hematoxylin and eosin.
For multicolor immunofluorescence, sections were fixed with acetone
and then incubated with the fibroblast marker ER-TR7 for 1 hour at 20°C.
The binding of the ER-TR7 was detected by incubation with FITC-
conjugated anti–rat IgG (Pharmingen). After each incubation or fixation,
the sections were gently washed twice in PBS, then mounted in PermaFlow
(Shandon, CA), and observed under a confocal microscope (MRC-1024;
Bio-Rad, Herts, United Kingdom).
Statistical analysis
The Dunnet multiple comparison test was used to assess the statistical
significance of differences after a one-way analysis of variance; a value of P
less than.05 was considered significant.
Results
Absence of antigen-induced granulation tissue formation in
MGL1-deficient mice
Sections were prepared from skin samples derived from the
exterior of the air pouch after the antigenic challenge. The
sections were histologically compared between wild-type and
MGL1-deficient mice. Representative results of the skin ob-
tained from mice on day 4 are shown in Figure 1A-B.
Development of granulation tissues in the subdermal areas was
evident in wild-type mice, whereas the formation of such tissue
was not observed in MGL1-deficient mice. Similar results were
obtained with skin samples prepared at days 11 and 18 (data not
shown). The thickness between the muscle fiber layer and the
inner surface of the air pouch was microscopically determined
as described.31 Nine arbitrarily selected fields in 5 sections
independently prepared from each mouse were used for each
measurement. The mean values of 45 measurements for an
individual mouse are plotted in Figure 1K. On day 4, the
presence of granulation tissue was evident in wild-type mice but
not in MGL1-deficient mice. The thickness of the granulation
tissue increased after the second challenge and persisted in
wild-type mice. Formation of the granulation tissue was not
observed in MGL1-deficient mice even after the second anti-
genic challenge, except for one mouse that produced a moderate
formation of the tissue on day 18. Therefore, we concluded that
formation of granulation tissue was severely impaired in MGL1-
deficient mice.
The absence of MGL1 in the MGL1-deficient mice was confirmed
in the inflamed skin by immunohistochemistry (Figure 1C-J).
Figure 1. Lack of granulation tissue formation in MGL1-deficient mice. (A-J) Samples of inflamed skin covering the dorsal air pouch were collected on day 4 from wild-type
(WT) or MGL1-deficient (KO) mice. Frozen sections were prepared and stained with hematoxylin and eosin (H.E.), with mAb LOM-14 that is reactive with both MGL1 and
MGL2, with mAb LOM-8.7 that is reactive only with MGL1, and with mAb URA-1 that is reactive with MGL2, or mouse IgG. The binding of mAbs was immunohistochemically
detected using biotin anti–rat / mAb plus alkaline phosphatase-streptavidin. (K) Specimens of inflamed skin covering the dorsal air pouch were collected on days 4, 11, and
18. The thickness of the granulation tissue (ordinate) was microscopically determined by measuring the hypodermis region between the muscle fiber layer and the inner surface
of the air pouch. Each symbol represents the thickness of an individual wild-type mouse (open symbols) or MGL1-deficient mouse (filled symbols). Wild-type mice developed
granulation tissues at the site of chronic antigenic stimulation, whereas MGL1-deficient mice did not. M represents muscle fiber layer. Bars represent 100 m (A,B) or 10 m
(D-J). Arrows indicate positively stained cells with the mAbs. *P  .05, **P  .001.
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Cells recognized by mAb LOM-14 (MGL1 and MGL2 cross-
reactive) were present in the dermis of wild-type and MGL1-
deficient mice. In contrast, cells recognized by mAb LOM-8.7
(MGL1-specific) were seen only in wild-type mice and were absent
from MGL1-deficient mice. The results indicated the absence of
MGL1 proteins but the presence of related protein MGL2 in the
dermis of MGL1-deficient mice, which was also shown by an
anti-MGL2 mAb URA-1. Cells recognized by mAb LOM-14 and
mAb LOM-8.7 were also observed within the granulation tissue in
the wild-type mice. The results strongly suggest that MGL1 is
required for granulation tissue formation induced by repeated local
antigenic stimulation.
Characterization of cells in the air pouch fluid
Cells in the pouch fluid were collected from MGL1-deficient
and wild-type mice on days 1 to 5, and the numbers of the cells
were compared (Figure 2G). On day 1, similar numbers of cells
were obtained between wild-type and MGL1-deficient mice.
The number of cells gradually decreased, though the decrease
was slower in MGL1-deficient mice than in wild-type mice. To
characterize these cells, flow cytometric analysis was per-
formed. The predominant population of the cells recovered from
the air pouch on day 1 was CD11b-positive/CD45-positive/Ly6G-
positive/major histocompatibility complex (MHC) class II–
negative in both MGL1-deficient and wild-type mice (data not
shown). Thus, the cells that migrated into this compartment on
day 1 mainly consisted of neutrophils. There was no difference
in the cell numbers between MGL1-deficient and wild-type
mice. On days 3 to 5, the cells in wild-type mice expressed
CD45 (Figure 2B on day 4) or CD11b (Figure 2B on day 4), and
a portion of the cells displayed MGL1/2 (Figure 2B on day 4),
moma-2, F4/80, Ly6G, or MHC class II, but not CD11c. We
concluded that the cells that migrated into the pouch during this
period in wild-type mice consisted of a mixture of macrophages,
neutrophils, and leukocytes. In the case of the cells from MGL1-
deficient mice, they apparently contained macrophages, neutrophils,
and other leukocytes, yet there were cells that were hardly reactive
with known markers of cells of myeloid origins (Figure 2E). In the
scatter profiles, cells smaller in size than leukocytes were promi-
nent in MGL1-deficient mice (Figure 2A,D). These cells, which
were gated in Figure 2D, did not express MGL1/2, CD11b, CD45,
F4/80, moma-2 (Figure 2F), Ly6G, MHC class II, or CD3 (data not
shown). Cells gated to the same area from wild-type mice, though
the number was small, were also examined. As shown in Figure 2C,
there were cells expressing CD11b/CD45/MGL1/2. Interestingly,
there were cells that were not reactive with any of the antibodies
used in both MGL1-deficient and wild-type mice. While CD45 is a
common leukocyte antigen, these unstained cells do not seem to
correspond to leukocytes or lymphocytes. The proportion of these
unstained cells was significantly greater in MGL1-deficient mice
than in wild-type mice. CD3-positive T cells were observed on
days 3 and 4 in cells from MGL1-deficient and wild-type mice
(data not shown) and T cells were supposed to be involved in the
formation of granulation tissue since the process was antigen-specific.
Effects of in vivo treatment with anti-MGL1 mAb LOM-8.7
on the formation of granulation tissue in chronic phase
To examine the roles of MGL1 in the granulation tissue, an
antibody against MGL1 was repeatedly injected into the air
pouch during the secondary antigenic challenge in wild-type
mice. As shown in Figure 3A-E, antibody treatment caused
formation of granulation tissue to be blocked by approximately
40%. By histologic analysis, areas close to the inner surface of
the air pouch seemed to be impaired. Furthermore, the mass of
the granulation tissues was significantly thinner in the pouch
treated with anti-MGL1 mAb LOM-8.7 than in the pouch treated
with saline or control IgG, as observed on days 11 and 18
(Figure 3F). The granulation tissue was removed and the number
of cells recovered from the tissue by collagenase digestion was
compared. On day 11, 3.3  106 and 1.9  106 cells per mouse
Figure 2. Characterization of the cells in the pouch fluid. The cells in the pouch
fluid were collected from both MGL1-deficient (closed square in G) and wild-type
(open square in G) mice on days 1 to 5, and the number of cells was counted (G).
Using the cells on day 4 from both wild-type (A-C) and MGL1-deficient mice (D-F), the
expression of MGL1/2, CD11b, CD45, F4/80, or moma-2 was analyzed by flow
cytometry. Flow cytometric scatter profiles of the cells are shown in panels A and D
(SS, side scatter; FS, forward scatter). The expressions of MGL1/2, CD11b, or CD45
on the cells in panel A or D are shown in panels B and E. Open histograms in panels B
and E represent staining with control mAb. The expressions of MGL1/2, CD11b,
CD45, F4/80, or moma-2 on cells in the subpopulation circled in panel A (wild-type)
and panel D (MGL1-deficient) are shown in panel C and panel F, respectively. The
number of cells recovered from the pouch fluid of MGL1-deficient mice was greater
than that recovered from wild-type mice. Furthermore, there was a predominant
subpopulation having a unique cell surface phenotype of CD11b-negative/CD45-
negative/MGL1/2-negative/F4/80-negative/moma-2–negative in MGL1-deficient mice.
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were obtained from the control IgG-treated and anti-MGL1–
treated groups, respectively. On day 18, the figures were
4.5  106 and 2.7  106, respectively. These data confirmed
that the number of cells in the granulation tissue was reduced on
treatment with anti-MGL1 antibody.
Effects of in vivo treatment with anti–IL-1 mAb on the
formation of granulation tissue in the chronic phase
The cytokine profile of isolated MGL1/2-positive cells from the
granulation tissue previously suggested that IL-1 was pro-
duced and secreted from MGL-positive cells.31 To study the
biologic roles of IL-1 locally produced by MGL1/2-positive
cells, an antibody against IL-1 was repeatedly injected into the
air pouch during the secondary antigenic challenge. Similar to
the anti-MGL1 mAb treatment, the thickness of the granulation
tissues was significantly less in the air pouch of mice treated
with anti–IL-1 mAb than was the case with those treated with
saline, as observed on days 11 and 18 (Figure 3). Immunohisto-
chemical data indicated that MGL1/2-positive cells shown by
the binding of mAb LOM-14 almost disappeared from an area
distant from the inner surface of the air pouch. In contrast,
MGL1/2-positive cells were still observed in the dermis after
antibody treatment. In contrast, the number of CD11b-positive
cells in the tissue did not decrease after treatment with
anti–IL-1 (data not shown). These results suggested that IL-1
plays a significant role in the accumulation of MGL1/2-positive
cells, particularly in the chronic phases.
Effects of in vivo treatment with recombinant mouse IL-1
on the formation of granulation tissue
To confirm the involvement of IL-1 in the impairment of the
antigen-induced tissue formation in MGL1-deficient mice, recom-
binant mouse IL-1 was injected into the air pouch on day 0 of the
antigenic challenge. Development of granulation tissue was ob-
served by IL-1 treatment in MGL1-deficient mice (71.1% of the
wild-type mice), whereas IL-1 did not show any effects in
wild-type mice (Figure 4A). In other experiments, recombinant
mouse IL-1 was injected along with the secondary antigenic
challenge on day 5 in order to confirm the effects of IL-1 on tissue
formation in the chronic phase. As shown in Figure 4B, granulation
tissue formation in a chronic phase was also induced and the
recovery was calculated to be 56.5%. There was no morphologic
difference in the granulation tissue between wild-type and MGL1-
deficient mice (data not shown). Thus, the effect of MGL1-
deficient status on antigen-induced granulation tissue formation
was likely to be mediated by the local absence of IL-1.
Figure 3. Effects of anti–IL-1 Ab and anti-MGL1 mAb LOM-8.7 on the formation
of granulation tissue after the second antigenic challenge in the air pouch. An
antigenic challenge was performed in the air pouch on days 0 and 5. Anti–IL-1 mAb,
anti-MGL1 mAb LOM-8.7, or saline was subsequently injected into the air pouch on
days 5, 6, and 7. Skin samples were collected on day 18 and frozen sections were
prepared. (A-E) Tissue stained with hematoxylin and eosin from mAb LOM-8.7–
treated mice (A), hematoxylin and eosin–stained tissue obtained from anti–IL-1–
treated mice (B), immunohistochemical staining profiles with mAb LOM-14 (anti-
MGL1/2) are shown (C-E). A boxed area and a dotted boxed area in panel C are
shown at higher magnifications in D and E, respectively. Very similar profiles were
obtained from samples prepared on day 11 (data not shown). Scale bars represent
100 m (A-C) and 10 m (D-E). (F) Thickness of the granulation tissue as indicated
with dotted lines in panels A and B is shown (ordinate) on days 11 and 18. f
represents saline-treated mice; `, control rat IgG instead of mAb; p, anti-IL-1–
treated mice; and , anti-MGL1 mAb LOM 8.7. Mean  standard error (SE; n 	 4).
Treatment with anti–IL-1 mAb significantly inhibited the formation of granulation
tissues as well as the infiltration of MGL1/2-positive cells in the area far from the inner
surface of the air pouch. Resident MGL1/2-positive cells in the dermis were still
observed. *P  .05, **P  .01.
Figure 4. Effects of IL-1 on the formation of antigen-induced
granulation tissue in the air pouch. (A) An antigen challenge was
performed in the air pouch and recombinant murine IL-1 (5 g/
mouse) was injected into the pouch on day 0. (B) Skin samples from
the air pouch were collected on day 4 (A) and day 11 (B) and frozen
sections were prepared. The thickness of the granulation tissue is
shown.  indicates wild-type mice; f, MGL1-deficient mice. Mean
plus or minus SE (n 	 3). Treatment with IL-1 induced the formation
of the granulation tissues at transient and chronic phases. *P  .05,
**P  .001. ns indicates not significant.
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Fate of cells obtained from the pouch of MGL1-deficient mice
after injection with recombinant mouse IL-1
As shown in Figure 2, the number of free cells recovered from
the pouch in MGL1-deficient mice was greater than that in
wild-type mice. Furthermore, a CD45-negative/CD11b-negative
population was predominant only in MGL1-deficient mice. To
determine the role of IL-1 in the association of these cells with
the granulation tissue, the number and identity of cells isolated
from the air pouch were determined after the administration of
IL-1. Injection of IL-1 reduced the number of CD45-negative/
CD11b-negative cells to a level similar to that of wild-type mice
(Figure 5B,D,F). The size of these cells became similar to that of
wild-type mice (Figure 5A,C,E). Total numbers of migrated
cells also decreased to a level similar to that found in wild-type
mice (Figure 5G). After IL-1 treatment, the percentage of
CD45-negative cells (fibroblast-like cell) significantly de-
creased from 56.3% to 2.5%. The value was similar to the level
in wild-type mice (1.8%). CD45-negative/CD11b-negative cells
were collected from the pouch fluid in MGL1-deficient mice 3
days after the antigenic challenge. These were labeled with
PKH-26 and were injected with or without IL-1 into the pouch
of MGL1-deficient mice. Granulation tissue formation was
observed only when IL-1 was provided and, as observed by the
fluorescence of PKH-26, the distribution of the injected cells
overlapped with that of cells stained with mAb ER-TR7–
positive fibroblasts (Figure 6). These results suggest that the
impairment of migration of the CD45-negative/CD11b-negative
pouch cells to the granulation tissue in MGL1-deficient mice
was also due to a local shortage in IL-1 and that CD45-
negative cells in MGL1-deficient mice represent precursors of
fibroblasts.
MGL1-deficient mice can mount an immune response against
T-cell–dependent antigen
To determine whether or not the lack of MGL1 could affect
initiation of immune responses against ABA-AcBSA, IgG
production was compared between wild-type and MGL1-
deficient mice. Mice were immunized with a mixture of antigen
and CFA, and challenged twice by subcutaneous application of
the antigen directly into the dorsal air pouch. During the
immunization and the antigenic challenge, total IgG concentra-
tion (Table 1) and ABA-AcBSA–specific IgG levels (Figure
7B-C) in sera were determined. After each challenge, serum IgG
concentrations increased; no difference showed in the level of
total IgG between wild-type and MGL1-deficient mice. Further-
more, the antigen-specific IgG levels increased similarly regard-
less of whether wild-type or MGL1-deficient mice were used.
The involvement of MGL1 on antigen-specific T-cell prolif-
eration was also examined. The splenocytes were obtained
from the mice that had been intradermally injected with the
antigen-CFA mixture 3 weeks earlier. The cells were cultured
with various concentrations of antigen for 5 days, and DNA syn-
thesis was assessed by [3H]-thymidine incorporation. There
were no differences in proliferative response to the antigen
between MGL1-deficient mice and wild-type mice (Figure 7A).
Figure 5. Effects of IL-1 on the cells recovered from
the pouch. An antigenic challenge was performed and
recombinant murine IL-1 (5 g/mouse) or PBS was
injected into the air pouch of MGL1-deficient or wild-type
mice on day 0. The cells in the pouch fluid were collected
from wild-type mice that were treated with PBS (A-B) and
MGL1-deficient mice treated with PBS (C-D) or with IL-1
(E-F) on day 3. To examine the effect of IL-1, the
expression of CD11b or CD45 on these cells was ana-
lyzed by flow cytometry (B,D,F). Flow cytometric scatter
profiles of these cells are also shown (A,C,E). Open
histograms in panels B, D, and F represent the staining
with control mAb. The number of cells recovered from the
pouch was counted and plotted in panel G. The number
of cells in the pouch fluid obtained from MGL1-deficient
mice was greater than that from wild-type mice or that
from MGL1-deficient mice injected with IL-1. Injection of
IL-1 also reduced the number of CD11b-negative/CD45-
negative subpopulations in the air pouch of MGL1-
deficient mice to a level similar to that of wild-type mice.
Similar data were obtained on day 4.
Figure 6. Examination of the cells recovered from the
pouch fluid obtained from MGL1-deficient mice. An
antigenic challenge was performed and cells in the pouch
were collected on day 3. The CD45-negative cells were
separated from the pouch fluid cell suspensions by
MACS and were labeled with PHK-26. The labeled cells
mixed with IL-1 (50 g/mL) were injected into the pouch
on MGL1-deficient mice on day 3. The injected cells,
which were labeled with PKH26 (B), were shown also to
be ER-TR7–positive and classified into fibroblasts (A).
Bars represent 5 m.
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These results indicated that MGL1 is not essential for the
initiation of immune responses such as antigen-specific T-cell
proliferation and T-cell–dependent IgG production in this system.
Discussion
Many macrophage functions are mediated by lectins. For example,
mice deficient in macrophage mannose receptors exhibited de-
creased clearance of peptide hormones with sulfated N-acetylgalac-
tosamine residues, although these mice showed similar susceptibil-
ity to the infections of Candida albicans and Pneumocystis
carinii.34-37 Galectin-3–deficient mice showed reduced recruitment
of neutrophils into inflamed peritoneal cavities38; macrophages
from these mice showed suppressed spreading and phagocytic
functions and the mice developed glomerulopathy under diabetic
conditions.39-41
MGL1 belongs to a large family of calcium-type lectins that
include cell surface molecules such as type 2 transmembrane
proteins, type 1 multilectins, selectins, humoral components such
as collectins,42 and extracellular matrix components such as
aggrecan.43 Earlier studies have reported that macrophage func-
tions were not strongly impaired in MGL1-deficient mice.26 There
was no abnormality in the controlled T-cell development, alloge-
neic cytotoxic T lymphocyte (CTL) responses, hematopoiesis, or
turnover of red blood cells.26 Lack of phenotypes might be
attributed to the presence of other macrophage C-type lectins with
similar carbohydrate specificity. Subsequently, MGL2, which poten-
tially substitutes MGL1 function, was identified on similar cell
populations.21 However, it is presently not known whether or not
these 2 isolectins share similar functions.
In the present study, we found a remarkable phenotype in
MGL1-deficient mice (Figure 1). The tissue remodeling associated
with a chronic immune response was almost completely absent in
mice deficient in MGL1. This result was reinforced by experiments
in which the administration of mAb LOM-8.7 (specific for MGL1)
into the air pouch during the second antigenic challenge also
suppressed the granulation tissue maintenance (Figure 3). Although
the connective tissue macrophages isolated from the dermis
covering the air pouch expressed MGL2 (Figure 1), the cells that
migrated into the pouch expressed MGL1 but not MGL2 (data not
shown). These results and the impairment of granulation tissue
formation in the MGL1-deficient mice that express MGL2 sug-
gested that MGL1 plays the primary role in this process. There was
no difference in the proliferative response to the antigen ABA-
AcBSA or in the synthesis of IgG antibodies specific for the antigen
between wild-type and MGL1-deficient mice (Figure 7) after the
immunization. As described in “Results,” CD3-positive T cells
were identified on days 3 and 4 in the air pouch of MGL1-deficient
or wild-type mice. These observations strongly suggest that T cells
were recruited to the inflammatory sites, even in the absence of
MGL1. Thus, we conclude that the defect in granulation tissue
formation in MGL1-deficient mice was not due to a lack of a
T-cell–specific immune response.
To understand the process of granulation tissue formation, the
involvement of cytokines was examined. MGL1/2-positive macro-
phages in the granulation tissue produced IL-1, and this was
confirmed by immunohistochemical analysis.31 As demonstrated in
this report, the importance of IL-1 as an effector molecule was
further confirmed by the use of anti–IL-1 antibody treatment to
block granulation tissue formation (Figure 3), and by the use of
recombinant IL-1 in MGL1-deficient mice (Figure 4) to “rescue”
the response. As shown in Figure 2, flow cytometric analysis of the
cells collected from the pouch fluid in MGL1-deficient mice
showed that a significant population of the cells were neither
myelomonocytic nor lymphocytic based on the expression of
CD45, CD11b, Ly6G, or MHC class II (data not shown). Similar
cells were obtained from wild-type mice in a much smaller number.
The number of these cells declined to a similar level in the
wild-type mice after IL-1 administration (Figure 5). Cell entry
Figure 7. Evaluation of antigen-specific immune response in MGL1-deficient mice. (A) Mice (, wild type; f, MGL1-deficient) were intradermally immunized with
ABA-AcBSA and the spleen was taken 3 weeks after immunization. Splenocyte proliferation in response to ABA-AcBSA (ordinate) expressed as the ratio of the [3H]-thymidine
incorporation count per minute (cpm) given by cells exposed to ABA-AcBSA to the cpm given by unexposed cells. Each value represents mean plus or minus SD (n 	 6). (B-D)
In other experiments, wild-type mice (B; open symbols) and MGL1-deficient mice (C; closed symbols) were subcutaneously immunized with ABA-AcBSA on day 
10, and were
subsequently challenged by injecting the antigen into the dorsal air pouch on days 0 and 5. Sera were collected on days 
10, 4, 11, and 18. Each serum sample was prepared
from 5 mice. The binding of IgG to immobilized ABA-AcBSA (ordinate) was measured for serum samples collected on days 
10 (no symbol), 4 (circles), 11 (triangles), and 18
(squares) and plotted to the serum dilution (abscissa) as determined by means of an ELISA.
Table 1. IgG by time after first challenge
Mouse
genotype
IgG by time after first challenge, g/mL, mean  SEM
10 d 4 d 11 d 18 d
WT 102.6  3.4 650.0  87.8* 832.1  97.0* 860.8  211.4*
KO 99.1  3.7 694.0  80.2* 717.7  165.9* 853.6  231.3*
Total IgG concentration in the serum from individual mice (n 	 3) was measured
by an ELISA.
*Difference is statistically significant (P  .001) compared with the value on day

10. Antigen-specific immune responses between MGL1-deficient mice and wild-
type mice were almost identical.
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from pouch fluid to the tissue seemed to be regulated by IL-1,
which was produced by MGL1/2-positive cells. We conclude that
the cells from granulation tissue injected with IL-1 are likely to be
fibroblasts because they were found to express the mAb ER-TR7
epitope (Figure 6).
Accumulation of fibroblasts and synthesis of collagen by these
cells are important events in granulation tissue formation.44 These
processes are known to require IL-1.7,9,45,46 We hypothesize that
the lack of IL-1 caused the failure of fibroblasts to activate the
synthesis and secretion of collagen and the formation of granula-
tion tissue in the inflamed tissue of MGL1-deficient mice. MGL1
molecule was assumed to regulate trafficking and localization of
MGL1-positive cells that produce and secrete IL-1. The lineage
origin and the distribution of MGL1-positive cells are important
areas to be investigated. In addition, identification of the ligands
for MGL1 in the inflammatory tissue and identification of the
cells carrying these ligands will directly prove this hypothesis in
the future.
Previous work has shown that MGL1-positive macrophages and
DCs develop from bone marrow myeloid cells.22 In humans,
MGL-positive macrophages and DCs can be developed from
monocytes.47,48 It is likely that dermal MGL-positive cells are
derived from these cells. Migration of dermal MGL1/2-positive
cells from dermis to draining lymph nodes was shown to be
initiated by IL-1.28 In a skin explant model, anti–IL-1 or
anti–IL-1 inhibited emigration of MGL1/2-positive cells from the
dermis.28 Therefore, IL-1 is also expected to activate macrophage
migration and initiate a positive feedback loop in the chronic
inflammatory process. Local availability of IL-1 must be severely
impaired by the lack of MGL1, due perhaps to deteriorated
trafficking of MGL1-positive cells, because this population of
macrophages produces IL-1. Under such conditions, fibroblasts
seem to be unable to remodel the surrounding tissue. Granulation
tissue formation is also known for its complex regulation through a
network of cytokines that includes transforming growth factor ,
tumor necrosis factor , IL-6, interferon , and IL-1/.49 The
involvement of these other cytokines in MGL1-dependent granula-
tion tissue formation will be examined in the future.
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